Literature DB >> 11854770

Medicinal use of cannabis: history and current status.

H Kalant1.   

Abstract

OBJECTIVE: To provide an overview of the history and pharmacology of cannabis in relation to current scientific knowledge concerning actual and potential therapeutic uses of cannabis preparations and pure cannabinoids.
METHODS: The literature on therapeutic uses of cannabis and cannabinoids was assessed with respect to type of study design, quality and variability of data, independent replications by the same or other investigators, magnitude of effects, comparison with other available treatments and reported adverse effects. The results of this review were also compared with those of major international reviews of this topic in the past five years.
CONCLUSIONS: Pure tetrahydrocannabinol and several analogues have shown significant therapeutic benefits in the relief of nausea and vomiting, and stimulation of appetite in patients with wasting syndrome. Recent evidence clearly demonstrates analgesic and anti-spasticity effects that will probably prove to be clinically useful. Reduction of intraocular pressure in glaucoma and bronchodilation in asthma are not sufficiently strong, long lasting or reliable to provide a valid basis for therapeutic use. The anticonvulsant effect of cannabidiol is sufficiently promising to warrant further properly designed clinical trials. There is still a major lack of long term pharmacokinetic data and information on drug interactions. For all the present and probable future uses, pure cannabinoids, administered orally, rectally or parenterally, have been shown to be effective, and they are free of the risks of chronic inflammatory disease of the airways and upper respiratory cancer that are associated with the smoking of crude cannabis. Smoking might be justified on compassionate grounds in terminally ill patients who are already accustomed to using cannabis in this manner. Future research will probably yield new synthetic analogues with better separation of therapeutic effects from undesired psychoactivity and other side effects, and with solubility properties that may permit topical administration in the eye, or aerosol inhalation for rapid systemic effect without the risks associated with smoke inhalation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11854770     DOI: 10.1155/2001/469629

Source DB:  PubMed          Journal:  Pain Res Manag        ISSN: 1203-6765            Impact factor:   3.037


  36 in total

1.  Population pharmacokinetic model of THC integrates oral, intravenous, and pulmonary dosing and characterizes short- and long-term pharmacokinetics.

Authors:  Jules A A C Heuberger; Zheng Guan; Olubukayo-Opeyemi Oyetayo; Linda Klumpers; Paul D Morrison; Tim L Beumer; Joop M A van Gerven; Adam F Cohen; Jan Freijer
Journal:  Clin Pharmacokinet       Date:  2015-02       Impact factor: 6.447

2.  Medical use of cannabis products: Lessons to be learned from Israel and Canada.

Authors:  J Ablin; P A Ste-Marie; M Schäfer; W Häuser; M-A Fitzcharles
Journal:  Schmerz       Date:  2016-02       Impact factor: 1.107

3.  CB1 cannabinoid receptor-mediated modulation of food intake in mice.

Authors:  Jenny L Wiley; James J Burston; Darnica C Leggett; Olga O Alekseeva; Raj K Razdan; Anu Mahadevan; Billy R Martin
Journal:  Br J Pharmacol       Date:  2005-06       Impact factor: 8.739

Review 4.  Cannabinoids in the Management of Musculoskeletal or Rheumatic Diseases.

Authors:  Mary-Ann Fitzcharles; Winfried Häuser
Journal:  Curr Rheumatol Rep       Date:  2016-12       Impact factor: 4.592

5.  Cannabinoids as therapeutic agents in cardiovascular disease: a tale of passions and illusions.

Authors:  V E Mendizábal; E Adler-Graschinsky
Journal:  Br J Pharmacol       Date:  2007-04-23       Impact factor: 8.739

6.  Gaps in predicting clinical doses for cannabinoids therapy: Overview of issues for pharmacokinetics and pharmacodynamics modelling.

Authors:  Zheng Liu; Jennifer H Martin
Journal:  Br J Clin Pharmacol       Date:  2018-06-07       Impact factor: 4.335

Review 7.  Medical marijuana initiatives : are they justified? How successful are they likely to be?

Authors:  Wayne Hall; Louisa Degenhardt
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 8.  [Cannabinoids in the treatment of the cachexia-anorexia syndrome in palliative care patients].

Authors:  F Nauck; E Klaschik
Journal:  Schmerz       Date:  2004-06       Impact factor: 1.107

Review 9.  Cannabinoids for fibromyalgia.

Authors:  Brian Walitt; Petra Klose; Mary-Ann Fitzcharles; Tudor Phillips; Winfried Häuser
Journal:  Cochrane Database Syst Rev       Date:  2016-07-18

10.  Randomized placebo-controlled double-blind clinical trial of cannabis-based medicinal product (Sativex) in painful diabetic neuropathy: depression is a major confounding factor.

Authors:  Dinesh Selvarajah; Rajiv Gandhi; Celia J Emery; Solomon Tesfaye
Journal:  Diabetes Care       Date:  2009-10-06       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.